International Journal of Nanomedicine (Jan 2012)

5-Fluorouracil-loaded poly(ε-caprolactone) nanoparticles combined with phage E gene therapy as a new strategy against colon cancer

  • Ortiz R,
  • Prados J,
  • Melguizo C,
  • Arias JL,
  • Ruíz MA,
  • Álvarez PJ,
  • Caba O,
  • Luque R,
  • Segura A,
  • Aránega A

Journal volume & issue
Vol. 2012, no. default
pp. 95 – 107

Abstract

Read online

Raúl Ortiz1,3, José Prados1, Consolación Melguizo1, José L Arias2, M Adolfina Ruiz2, Pablo J Álvarez1, Octavio Caba1,3, Raquel Luque4, Ana Segura5, Antonia Aránega11Institute of Biopathology and Regenerative Medicine (IBIMER), 2Department of Pharmacy and Pharmaceutical Technology, University of Granada, Granada, Spain; 3Department of Health Science, University of Jaén, Jaén, Spain; 4Service of Medical Oncology, Virgen de las Nieves Hospital, Granada, Spain; 5CSIC-Estacion Experimental del Zaidin, Department of Environmental Protection, Granada, SpainAbstract: This work aimed to develop a new therapeutic approach to increase the efficacy of 5-fluorouracil (5-FU) in the treatment of advanced or recurrent colon cancer. 5-FU-loaded biodegradable poly(ε-caprolactone) nanoparticles (PCL NPs) were combined with the cytotoxic suicide gene E (combined therapy). The SW480 human cancer cell line was used to assay the combined therapeutic strategy. This cell line was established from a primary adenocarcinoma of the colon and is characterized by an intrinsically high resistance to apoptosis that correlates with its resistance to 5-FU. 5-FU was absorbed into the matrix of the PCL NPs during synthesis using the interfacial polymer disposition method. The antitumor activity of gene E from the phage ΦX174 was tested by generating a stable clone (SW480/12/E). In addition, the localization of E protein and its activity in mitochondria were analyzed. We found that the incorporation of 5-FU into PCL NPs (which show no cytotoxicity alone), significantly improved the drug's anticancer activity, reducing the proliferation rate of colon cancer cells by up to 40-fold when compared with the nonincorporated drug alone. Furthermore, E gene expression sensitized colon cancer cells to the cytotoxic action of the 5-FU-based nanomedicine. Our findings demonstrate that despite the inherent resistance of SW480 to apoptosis, E gene activity is mediated by an apoptotic phenomenon that includes modulation of caspase-9 and caspase-3 expression and intense mitochondrial damage. Finally, a strongly synergistic antiproliferative effect was observed in colon cancer cells when E gene expression was combined with the activity of the 5-FU-loaded PCL NPs, thereby indicating the potential therapeutic value of the combined therapy.Keywords: colon cancer, combined therapy, 5-fluorouracil, gene therapy, E gene, poly (ε-caprolactone)